These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15952872)

  • 1. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.
    Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Lang F; Eichelbaum M; Strandberg T
    Am J Pharmacogenomics; 2005; 5(3):191-5. PubMed ID: 15952872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy.
    Lieb W; Bolbrinker J; Döring A; Hense HW; Erdmann J; Schunkert H; Kreutz R
    Clin Sci (Lond); 2006 Dec; 111(6):365-72. PubMed ID: 16822233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.
    Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K
    Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.
    Langaee TY; Gong Y; Yarandi HN; Katz DA; Cooper-DeHoff RM; Pepine CJ; Johnson JA
    Clin Pharmacol Ther; 2007 Mar; 81(3):386-91. PubMed ID: 17339868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.
    Givens RC; Lin YS; Dowling AL; Thummel KE; Lamba JK; Schuetz EG; Stewart PW; Watkins PB
    J Appl Physiol (1985); 2003 Sep; 95(3):1297-300. PubMed ID: 12754175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
    Lee SJ; Goldstein JA
    Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
    Rodríguez-Jiménez C; García-Saiz M; Pérez-Tamajón L; Salido E; Torres A
    Drug Metab Pers Ther; 2017 Mar; 32(1):49-58. PubMed ID: 28245187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
    Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
    Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
    J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population.
    Park SY; Kang YS; Jeong MS; Yoon HK; Han KO
    J Clin Pharm Ther; 2008 Feb; 33(1):61-5. PubMed ID: 18211618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
    Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
    Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
    Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
    Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
    Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.
    Torio A; Auyanet I; Montes-Ares O; Guerra RM; Fernandez EJ; Perez MA; Ramirez A; Checa MD
    Transplant Proc; 2012 Nov; 44(9):2596-8. PubMed ID: 23146466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the CYP3A5 genotype and blood pressure.
    Ho H; Pinto A; Hall SD; Flockhart DA; Li L; Skaar TC; Cadman P; O'Connor DT; Wagner U; Fineberg NS; Weinberger MH
    Hypertension; 2005 Feb; 45(2):294-8. PubMed ID: 15596575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.